R

    Rapid Micro Biosystems Inc (RPID)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.52
    -0.05 (-3.18%)

    Market Cap: $78.75M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    29%(6/21)
    Avg Surprise
    -239.56%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.20
    Range$-0.21 - $-0.19
    3 analysts
    EPS Revisions
    2
    0
    7d
    3
    0
    30d
    EPS Estimate Drift
    90d ago$-0.22-10.0%
    60d ago$-0.20+0.0%
    30d ago$-0.20+0.0%
    7d ago$-0.20+0.0%
    Current$-0.20
    Revenue Consensus
    $10M
    Range$9M - $11M
    4 analysts
    Dec 31, 2026
    EPS Consensus$-0.25
    Range$-0.26 - $-0.22
    3 analysts
    Revenue Consensus
    $14M
    Range$13M - $15M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.25---
    Sep 26EST
    		-$-0.20---
    Jun 26
    		$-0.27$-0.26-3.85%Miss+0.0%
    Mar 26
    		$-0.31$-0.21-47.62%Miss-19.2%
    Dec 25
    		$-0.28$-0.23-21.74%Miss-27.3%
    Sep 25
    		$-0.26$-0.24-8.33%Miss+0.0%
    Jun 25
    		$-0.27$-0.25-8.00%Miss+6.9%
    Mar 25
    		$-0.26$-0.27+3.70%Beat+16.1%
    Dec 24
    		$-0.22$-0.21-4.76%Miss+15.4%
    Sep 24
    		$-0.26$-0.25-4.00%Miss+16.1%
    Jun 24
    		$-0.29$-0.28-3.57%Miss+12.1%
    Mar 24
    		$-0.31$-0.29-6.90%Miss+3.1%
    Dec 23
    		$-0.26$-0.30+13.33%Beat+33.3%
    Sep 23
    		$-0.31$-0.28-10.71%Miss+18.4%
    Jun 23
    		$-0.33$-0.33+0.00%Beat-6.5%
    Mar 23
    		$-0.32$-0.36+11.11%Beat+8.6%
    Dec 22
    		$-0.39$-0.36-8.33%Miss-11.4%
    Sep 22
    		$-0.38$-0.36-5.56%Miss+2.6%
    Jun 22
    		$-0.31$-0.35+11.43%Beat+98.5%
    Mar 22
    		$-0.35$-0.32-9.38%Miss+49.3%
    Dec 21
    		$-0.35$-0.28-25.00%Miss-
    Sep 21
    		$-0.39$-0.39+0.00%Beat-
    Jun 21
    		$-20.01$-0.40-4902.50%Miss-
    Mar 21
    		$-0.69$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.36EV/EBITDA0.83x
    Price/FCF-1.80xFCF Yield-55.57%
    Profitability
    Profit Margin-145.60%Operating Margin-153.00%
    ROE-141.70%ROIC-135.11%
    Financial Health
    Debt/Equity1.08xInterest Coverage-25.56x
    Current Ratio2.55xQuick Ratio1.51x
    Trading Statistics
    Beta1.48Avg Volume241.45K
    52-Week High$4.9452-Week Low$1.52

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.63
    SMA 20$1.72
    SMA 50$1.84
    SMA 200$2.81
    EMA 10$1.63
    EMA 20$1.71
    EMA 50$1.84
    EMA 200$2.47

    MACD

    Line: -0.09Signal: -0.08Hist: -0.01

    ADX

    ADX: 27.3+DI: 12.8-DI: 24.7

    Aroon & PSAR

    Aroon Up20.0
    Aroon Down100.0
    PSAR$1.77

    Bollinger Bands

    Upper Band$2.05
    Lower Band$1.38
    %B Position3947%(Upper)
    Band Width0.21

    RSI (14-Day)

    Neutral
    30.9

    Momentum Oscillators

    Stoch %K20.9
    Stoch %D25.3
    Williams %R-86.2
    ROC (10d)-1.9%
    Momentum-0.03
    CCI (20d)-106.6
    MFI (14d)41.9

    Volatility Measures

    ATR (14d)$0.12(7.8%)
    StdDev (20d)0.17
    Hist Vol75.7%(High)

    Volume Flow

    VWAP$1.54
    OBV-16.4M
    AD Line7.1M
    CMF (20d)-0.335

    Volume Metrics

    Avg Vol (20d)247.6K
    Vol Ratio0.8x
    VWMA (20d)$1.70

    Pivot Points

    R3$1.70
    R2$1.66
    R1$1.62
    Pivot Point$1.58
    S1$1.54
    S2$1.50
    S3$1.46

    Advanced Oscillators

    TSI-27.43
    Ultimate Osc41.5
    KST-159.17

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$8.05M$8.00M$11.28M$7.84M$7.26M$7.21M$8.22M$7.60M$6.62M$5.61M$6.34M$6.14M
    Cost of Revenue$6.84M$7.63M$11.61M$7.14M$6.99M$6.80M$7.24M$6.98M$6.81M$7.13M$6.51M$7.78M
    Gross Profit$1.21M$371,000$-328,000$696,000$275,000$404,000$981,000$622,000$-189,000$-1,523,000$-172,000$-1,631,000
    Operating Expenses$13.53M$14.22M$11.88M$12.07M$12.42M$12.06M$11.21M$12.66M$13.19M$12.75M$12.02M$12.82M
    R&D$3.33M$3.36M$3.22M$3.53M$3.23M$3.62M$3.40M$3.61M$3.74M$3.84M$3.32M$3.12M
    SG&A$6.77M$7.44M$5.34M$5.64M$6.08M$5.69M$4.83M$5.68M$5.82M$5.63M$5.54M$6.20M
    Operating Income$-12,322,000$-13,852,000$-12,211,000$-11,372,000$-12,148,000$-11,661,000$-10,229,000$-12,039,000$-13,378,000$-14,273,000$-12,188,000$-14,449,000
    Interest Income$140,000$256,000$345,000$347,000$351,000$466,000$604,000$779,000$838,000$983,000$0$1.09M
    Interest Expense$646,000$639,000$272,000$393,000$12,000$12,000$0$11,000$0$0$0$0
    Income Before Tax$-12,878,000$-14,267,000$-12,483,000$-11,497,000$-11,847,000$-11,256,000$-9,675,000$-11,310,000$-12,563,000$-13,319,000$-11,164,000$-13,382,000
    Income Tax Expense$45,000$8,000$14,000$8,000$11,000$7,000$-9,000$13,000$15,000$3,000$8,000$10,000
    Net Income$-12,923,000$-14,275,000$-12,497,000$-11,505,000$-11,858,000$-11,263,000$-9,666,000$-11,323,000$-12,578,000$-13,322,000$-11,172,000$-13,392,000
    EBITDA$-11,613,000$-13,092,000$-11,341,000$-10,647,000$-11,375,000$-10,863,000$-9,381,000$-11,219,000$-12,573,000$-13,496,000$-11,411,000$-13,694,000
    EBIT$-12,372,000$-13,884,000$-12,131,000$-11,451,000$-12,186,000$-11,710,000$-10,250,000$-12,078,000$-13,401,000$-14,302,000$-12,205,000$-14,475,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RPID

    Government Contracts

    Gov Obligations (TTM)
    $39051
    Gov Obligations / Revenue
    0.1%
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    1
    Avg Remaining Term
    4.9 mo

    Top agency: Department of Defense at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    HT942626FE009Department of DefenseDefense Health Agency$39051Feb 9, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Armistice Capital (RPID) discloses 3.33M-share position in Rapid Micro Biosystems

    Armistice Capital, LLC and Steven Boyd have disclosed a 7.29% stake in Rapid Micro Biosystems, Inc. (RPID), amounting to 3,328,000 shares of Class A common stock. All voting and dispositive power over these shares is shared, with Armistice Capital acting as the investment manager for Armistice Capital Master Fund Ltd., which directly holds the shares. Steven Boyd is the managing member of Armistice Capital.

    Stock Titan•8/14/26•
    Neutral

    Rapid Micro Biosystems (RPID) major holder Bain updates Schedule 13G/A stake

    Bain Capital Life Sciences-affiliated funds have updated their stake in Rapid Micro Biosystems (RPID) Class A common stock through a Schedule 13G/A filing. As of June 30, 2026, Bain Capital Life Sciences Fund, L.P. beneficially owned 16.8% of outstanding shares, while BCIP Life Sciences Associates, LP held 1.7%. BCLS Investco, LP also holds warrants, but cannot exercise them if it would lead to beneficial ownership exceeding 9.99%, therefore these warrants are not currently considered beneficially owned under Rule 13d-3.

    Stock Titan•8/14/26•
    Neutral

    Rapid Micro Biosystems, Inc. (RPID) Leadership & Management Team Analysis

    This article provides an in-depth analysis of Rapid Micro Biosystems, Inc. (RPID)'s leadership, management team, and recent company updates. It highlights CEO Rob Spignesi's compensation and ownership, along with details on insider transactions, board changes, and financial risks. The company faces challenges such as unprofitability and a short cash runway but has reaffirmed revenue guidance for 2026, driven by growth in system placements and key partnerships.

    Simply Wall Street•8/8/26•
    Somewhat-Bearish

    Wall Street Analysts Are Bullish on Top Healthcare Picks

    Wall Street analysts are showing bullish sentiment towards several healthcare stocks. Specifically, Illumina (ILMN) received a Buy rating from Stifel Nicolaus with a $225 price target, and Travere Therapeutics (TVTX) was reiterated as a Buy by TD Cowen with a $75 price target. Both companies are highlighted for their potential in the healthcare sector, with analysts projecting upside for Travere Therapeutics despite a slight downside for Illumina from its consensus price target.

    The Globe and Mail•8/6/26•
    Neutral

    Rapid Micro Biosystems announces inducement grants

    Rapid Micro Biosystems, Inc. announced the grant of 90,000 restricted stock units and a non-qualified stock option to purchase 170,000 shares of its Class A common stock to a new employee. These awards, made under the company's Inducement Plan, are intended as a material inducement for employment and are subject to specific vesting schedules and continued employment. The stock option has an exercise price of $2.12 per share, matching the closing price on the grant date.

    Medical Buyer•8/5/26•
    Neutral

    Frequently Asked Questions About RPID

    Does RPID pay dividends?
    Rapid Micro Biosystems Inc (RPID) does not currently pay a regular dividend.
    What is RPID's market cap?
    Rapid Micro Biosystems Inc (RPID) has a market capitalization of $78.75M with a current stock price of $1.52.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In